PEPG

PepGen Ltd

PEPG, USA

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

https://pepgen.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PEPG
stock
PEPG

How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% WV News

Read more →
PEPG
stock
PEPG

A better buy-in window may exist right now for PepGen Inc (PEPG) Setenews

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

3

Buy

1

Hold

0

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.17

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.05 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.48 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.16

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 73.31% of the total shares of PepGen Ltd

1.

RA Capital Management, LLC

(32.5904%)

since

2025/06/30

2.

Point72 Asset Management, L.P.

(8.4122%)

since

2025/06/30

3.

Millennium Management LLC

(4.6013%)

since

2025/06/30

4.

Viking Global Investors LP

(4.5197%)

since

2025/06/30

5.

Adage Capital Partners Gp LLC

(4.1159%)

since

2025/06/30

6.

Vanguard Group Inc

(2.8568%)

since

2025/06/30

7.

LAURION CAPITAL MANAGEMENT LP

(2.4719%)

since

2025/06/30

8.

Woodline Partners LP

(2.1083%)

since

2025/06/30

9.

BlackRock Inc

(1.9757%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(1.4402%)

since

2025/07/31

11.

Suvretta Capital Management, LLC

(0.9146%)

since

2025/06/30

12.

Prosight Management, LP

(0.7438%)

since

2025/06/30

13.

Opaleye Management Inc

(0.7317%)

since

2025/06/30

14.

Geode Capital Management, LLC

(0.6131%)

since

2025/06/30

15.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6063%)

since

2025/07/31

16.

iShares Biotechnology ETF

(0.5223%)

since

2025/08/31

17.

Sphera Funds Management Ltd.

(0.477%)

since

2025/06/30

18.

Ikarian Capital, LLC

(0.4573%)

since

2025/06/30

19.

Vanguard Balanced Index Inv

(0.4516%)

since

2025/07/31

20.

RBF LLC

(0.3049%)

since

2025/06/30

21.

Fidelity Extended Market Index

(0.2818%)

since

2025/07/31

22.

Bridgeway Capital Management, LLC

(0.2803%)

since

2025/06/30

23.

Bridgeway Ultra-Small Company Market

(0.2406%)

since

2025/06/30

24.

Qube Research & Technologies

(0.2226%)

since

2025/06/30

25.

Goldman Sachs Group Inc

(0.2153%)

since

2025/06/30

26.

State Street Corp

(0.2108%)

since

2025/06/30

27.

Zacks Small-Cap Core Inv

(0.116%)

since

2025/05/31

28.

iShares Micro-Cap ETF

(0.1144%)

since

2025/08/31

29.

Extended Equity Market Fund K

(0.1142%)

since

2025/06/30

30.

Fidelity Total Market Index

(0.0935%)

since

2025/07/31

31.

Fidelity Series Total Market Index

(0.0763%)

since

2025/07/31

32.

Fidelity Nasdaq Composite Index

(0.0691%)

since

2025/07/31

33.

NT Ext Equity Mkt Idx Fd - L

(0.0619%)

since

2025/06/30

34.

Northern Trust Extended Eq Market Idx

(0.0619%)

since

2025/06/30

35.

Spartan Extended Market Index Pool F

(0.0575%)

since

2025/07/31

36.

iShares Nasdaq US Biotech ETF USD Acc

(0.0525%)

since

2025/08/31

37.

Spartan Total Market Index Pool G

(0.0341%)

since

2025/07/31

38.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0304%)

since

2025/07/31

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0304%)

since

2024/12/31

40.

NT Ext Equity Mkt Idx Fd - NL

(0.0301%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.52

EPS Estimate

-0.6283

EPS Difference

0.1083

Surprise Percent

17.237%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.